Onco,
Journal Year:
2024,
Volume and Issue:
4(4), P. 458 - 470
Published: Dec. 19, 2024
Background:
Patients
with
lung
cancer
experience
higher
rates
of
hospitalization
due
to
their
elevated
mortality
and
associated
comorbidities.
Hospital
admissions
among
oncology
patients
often
indicate
organ
vulnerability
are
linked
poor
prognosis.
This
study
aimed
assess
the
characteristics
potential
prognostic
factors
hospitalized
patients.
Methods:
We
retrospectively
analyzed
646
admitted
from
June
2021
May
2022
Medical
Oncology
Service
at
La
Paz
University
(Madrid,
Spain).
Results:
During
this
period,
158
had
(24.5%).
The
median
overall
survival
since
admission
(mOSSA)
was
3.3
months
(95%CI:
1.86–7.74).
In
univariate
analysis,
poorer
mOSSA
for
tumor-related
causes
(1.33
vs.
7.30
months,
p
<
0.001),
ECOG
≥
2
(2.43
8.50
NLR
6
(1.87
7.40
months),
PNI
≤
40
(1.67
4.97
LDH
210
(2.27
7.87
=
0.044).
multivariate
independent
included
(p
0.032,
aHR
1.81,
95%CI:
1.05–3.11)
0.041,
1.80,
1.03–3.16).
Conclusions:
is
a
event,
particularly
when
or
decline
in
performance
status.
Journal of Clinical Oncology,
Journal Year:
2024,
Volume and Issue:
42(21), P. 2500 - 2505
Published: June 3, 2024
Clinical
trials
frequently
include
multiple
end
points
that
mature
at
different
times.
The
initial
report,
typically
based
on
the
primary
point,
may
be
published
when
key
planned
co-primary
or
secondary
analyses
are
not
yet
available.
Trial
Updates
provide
an
opportunity
to
disseminate
additional
results
from
studies,
in
JCO
elsewhere,
for
which
point
has
already
been
reported.
Although
CNS
activity
of
selpercatinib
patients
with
RET
fusion-positive
non–small
cell
lung
cancer
(NSCLC)
previously
described,
ability
potent
inhibition
prevent
new
metastases
developing
challenging
measure
without
randomized
data.
Serial
scans
were
studied
LIBRETTO-431,
a
phase
III
trial
versus
platinum/pemetrexed
±
pembrolizumab
whose
have
disclosed.
Intracranial
outcomes
assessed
by
neuroradiologic
blinded
independent
central
review
baseline
and
≥1
postbaseline
scans.
Of
192
within
intention-to-treat
population
scans,
150
metastases.
cumulative
incidence
progression
these
was
reduced
chemotherapy
+
(cause-specific
hazard
ratio
[HR],
0.17
[95%
CI,
0.04
0.69]).
HR
intracranial
progression-free
survival
(PFS)
0.46
(95%
0.18
1.18).
Among
42
metastases,
similar
trends
observed
HR,
0.61
0.19
1.92])
PFS
(HR,
0.74
0.28
1.97]).
These
data
demonstrate
effectively
treats
existing
disease
prevents
delays
formation
reinforce
importance
identifying
fusions
first-line
NSCLC
treating
selpercatinib.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: June 7, 2024
Citation:
Gristina
V
and
Eze
C
(2024)
Editorial:
Real-world
data
real-world
evidence
in
lung
cancer.
Front.
Oncol.
14:1436077.
doi:
10.3389/fonc.2024.1436077
Journal of Clinical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 21, 2025
LIBRETTO-001
(ClinicalTrials.gov
identifier:
NCT03157128
)
is
a
registrational
phase
I/II,
single-arm,
open-label
trial
of
selpercatinib
in
RET-dependent
cancers.
With
19
months
additional
follow-up,
we
report
the
final
efficacy
and
safety
results
patients
with
RET
fusion–positive
non–small
cell
lung
cancer
(NSCLC)
who
had
previously
received
platinum-based
chemotherapy
(N
=
247)
or
were
treatment-naïve
69).
The
objective
response
rate
(ORR)
was
62%
for
pretreated
83%
patients.
Duration
(DoR)
31.6
20.3
(median
follow-up
approximately
38
months).
Median
progression-free
survival
(PFS)
26.2
22.0
40
overall
47.6
not
reached
group
43
At
3-year
landmark
estimate,
57%
66%
alive.
Among
26
measurable
CNS
metastases
at
baseline,
CNS-ORR
85%
CNS-DoR
9.4
CNS-PFS
11.0
months.
profile
consistent
previous
reports.
substantial
continued
to
show
durable
responses
intracranial
activity,
manageable
NSCLC.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(5), P. 2042 - 2042
Published: Feb. 26, 2025
The
development
of
tyrosine
kinase
inhibitors
(TKIs)
for
late-stage
epidermal
growth
factor
receptor
(EGFR)-mutant
non-small
cell
lung
cancer
(NSCLC)
represented
a
drastic
change
in
the
treatment
cancer.
Drug
resistance
develops
after
certain
period
first-line
TKI
treatment,
which
has
led
to
decades
changing
guidelines
EGFR-mutant
NSCLC.
This
study
discussed
potential
mechanisms
drug
against
and
successive
strategies.
Next-generation
sequencing
(NGS)
may
play
role
evaluation
treatment.
Emerging
combination
regimens
ongoing
trials
were
discussed.
Potential
future
strategies
management
proposed
this
study.
Journal of Clinical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 27, 2025
Living
guidelines
are
developed
for
selected
topic
areas
with
rapidly
evolving
evidence
that
drives
frequent
change
in
recommended
clinical
practice.
updated
on
a
regular
schedule
by
standing
expert
panel
systematically
reviews
the
health
literature
continuous
basis,
as
described
ASCO
Guidelines
Methodology
Manual
.
follow
Conflict
of
Interest
Policy
Implementation
Clinical
Practice
and
updates
not
intended
to
substitute
independent
professional
judgment
treating
clinician
do
account
individual
variation
among
patients.
See
appendix
disclaimers
other
important
information
(
Appendix
1
2
).
Updates
published
regularly
can
be
found
at
https://ascopubs.org/nsclc-da-living-guideline
